Acquisition of two treatments ‘rounds out’ Upsher-Smiths migraine portfolio

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/PeopleImages)
(Image: Getty/PeopleImages)

Related tags: acquistion, Migraine, Drug delivery, Drug delivery systems, intranasal, API, facility

The acquisition of two migraine therapies from Dr Reddy’s has been completed by Upsher-Smith, adding different drug delivery treatment options to its migraine product portfolio.

Upsher-Smith acquired Tosymra (sumatriptan) nasal spray and Zembrace SymTouch (sumatriptan) injection from Dr. Reddy’s Laboratories, as it continues to add to its migraine product portfolio.

Dr Reddy’s entered an asset purchase agreement​ with Upsher-Smith in June and the acquisition has now been completed. The agreement saw Upsher-Smith pay $70m (€62m) to acquire the rights of the two products in the US and other selected markets.

The transaction included an up-front cash payment, with a further $40.5m in near-term milestones and sales-based royalty payments included.

Before the acquisition, the products were commercialized through Dr. Reddy’s wholly-owned subsidiary Promus Pharma. The two therapies were Promus’ lead products, but the company has a pipeline including DFN-15 (oral liquid celecoxib) and DFN-19 (dihydroergotamine nasal spray).

Zembrace is already on the market and Tosymra has been approved. Both medications are indicated for the acute treatment of migraine in adults.

According to Upsher-Smith, more than thirty-six million Americans suffer from migraines.

The company’s current portfolio offers Qudexy XR (topirmate) extended-release capsules for the prevention of migraine headache in adults but the addition of Zembrace and Tosymra “rounds out Upsher-Smiths’ migraine product portfolio,” ​said a spokesperson for Upsher-Smith.

Upsher-Smith is preparing to launch Tosymra toward the end of 2019 and is working to ensure a transition of delivery for Zembrace SymTouch to patients as well.

 This acquisition is one of a number of moves from Dr Reddy’s to divest assets, following the decision to sell an active pharmaceutical ingredients (API) plant​ and antibiotics facility​ last year.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars